McLean Duncan J, Diaz-Gil Daniel, Farhan Hassan N, Ladha Karim S, Kurth Tobias, Eikermann Matthias
From the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts (D.J.M., D.D.-G., H.N.F., K.S.L., M.E.); Inserm Research Center for Epidemiology and Biostatistics (U897)-Team Neuroepidemiology, Bordeaux, France (T.K.); University of Bordeaux, College of Health Sciences, Bordeaux, France (T.K.); Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts (T.K.); and Universitaetsklinkum Duisburg-Essen, Essen, Germany (M.E.).
Anesthesiology. 2015 Jun;122(6):1201-13. doi: 10.1097/ALN.0000000000000674.
Duration of action increases with repeated administration of neuromuscular-blocking agents, and intraoperative use of high doses of neuromuscular-blocking agent may affect respiratory safety.
In a hospital-based registry study on 48,499 patients who received intermediate-acting neuromuscular-blocking agents, the authors tested the primary hypothesis that neuromuscular-blocking agents are dose dependently associated with the risk of postoperative respiratory complications. In the secondary analysis, the authors evaluated the association between neostigmine dose given for reversal of neuromuscular-blocking agents and respiratory complications. Post hoc, the authors evaluated the effects of appropriate neostigmine reversal (neostigmine ≤ 60 μg/kg after recovery of train-of-four count of 2) on respiratory complications. The authors controlled for patient-, anesthesia-, and surgical complexity-related risk factors.
High doses of neuromuscular-blocking agents were associated with an increased risk of postoperative respiratory complications (n = 644) compared with low doses (n = 205) (odds ratio [OR], 1.28; 95% CI, 1.04 to 1.57). Neostigmine was associated with a dose-dependent increase in the risk of postoperative respiratory complications (OR, 1.51; 95% CI, 1.25 to 1.83). Post hoc analysis revealed that appropriate neostigmine reversal eliminated the dose-dependent association between neuromuscular-blocking agents and respiratory complications (for neuromuscular-blocking agent effects with appropriate reversal: OR, 0.98; 95% CI, 0.63 to 1.52).
The use of neuromuscular-blocking agents was dose dependently associated with increased risk of postoperative respiratory complications. Neostigmine reversal was also associated with a dose-dependent increase in the risk of respiratory complications. However, the exploratory data analysis suggests that the proper use of neostigmine guided by neuromuscular transmission monitoring results can help eliminate postoperative respiratory complications associated with the use of neuromuscular-blocking agents.
神经肌肉阻滞剂重复给药后作用时间会延长,术中使用高剂量神经肌肉阻滞剂可能影响呼吸安全。
在一项基于医院登记系统的研究中,纳入了48499例接受中效神经肌肉阻滞剂的患者,作者检验了主要假设,即神经肌肉阻滞剂与术后呼吸并发症风险存在剂量依赖性关联。在二次分析中,作者评估了用于逆转神经肌肉阻滞剂作用的新斯的明剂量与呼吸并发症之间的关联。事后分析中,作者评估了适当的新斯的明逆转(四个成串刺激计数恢复至2后新斯的明≤60μg/kg)对呼吸并发症的影响。作者对患者、麻醉和手术复杂性相关的风险因素进行了控制。
与低剂量(n = 205)相比,高剂量神经肌肉阻滞剂与术后呼吸并发症风险增加相关(n = 644)(比值比[OR],1.28;95%可信区间[CI],1.04至1.57)。新斯的明与术后呼吸并发症风险的剂量依赖性增加相关(OR,1.51;95%CI,1.25至1.83)。事后分析显示,适当的新斯的明逆转消除了神经肌肉阻滞剂与呼吸并发症之间的剂量依赖性关联(对于适当逆转后的神经肌肉阻滞剂效应:OR,0.98;95%CI,0.63至1.52)。
神经肌肉阻滞剂的使用与术后呼吸并发症风险增加存在剂量依赖性关联。新斯的明逆转也与呼吸并发症风险的剂量依赖性增加相关。然而,探索性数据分析表明,根据神经肌肉传递监测结果合理使用新斯的明有助于消除与神经肌肉阻滞剂使用相关的术后呼吸并发症。